title: [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
abstract: Despite progress in the initial management of glioblastoma (GB), the vast majority of patients will experience recurrence within 2-3 years. The medical treatment of these recurrences is being modified by the use of antiangiogenic therapies. Twenty-four patients, who relapsed from GB after chemoradiation followed by adjuvant temozolomide in Rennes, were treated by conventional chemotherapy (nitrosourea) or by the combination of irinotecan and bevacizumab. In this retrospective analysis, overall survival from diagnosis of recurrence was significantly longer in patients treated with the combination of bevacizumab and irinotecan than with nitrosourea (5 months versus 11.5 months). The combination of irinotecan and bevacizumab appeared to provide clinical benefit to patients with recurrent GB.
authors.affiliation: Centre Eugène-Marquis, département d'oncologie médicale, CS 44229, 35042 Rennes Cedex, France, UMR 6061 CNRS, université de Rennes-I, IFR 140, CS34317, 35043 Rennes Cedex, France.
authors.forename: Elodie
authors.initials: E
authors.lastname: Vauleon
authors.forename: Habiba
authors.initials: H
authors.lastname: Mesbah
authors.forename: Daniel
authors.initials: D
authors.lastname: Gedouin
authors.forename: Isabelle
authors.initials: I
authors.lastname: Lecouillard
authors.forename: Guillaume
authors.initials: G
authors.lastname: Louvel
authors.forename: Abderrahmane
authors.initials: A
authors.lastname: Hamlat
authors.forename: Laurent
authors.initials: L
authors.lastname: Riffaud
authors.forename: Béatrice
authors.initials: B
authors.lastname: Carsin
authors.forename: Véronique
authors.initials: V
authors.lastname: Quillien
authors.forename: Odile
authors.initials: O
authors.lastname: Audrain
authors.forename: Thierry
authors.initials: T
authors.lastname: Lesimple
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002330:Carmustine / Q000008:administration & dosage; D059248:Chemoradiotherapy / Q000379:methods; D017024:Chemotherapy, Adjuvant / Q000379:methods; D015331:Cohort Studies; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004359:Drug Therapy, Combination / Q000379:methods; D005909:Glioblastoma / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D006801:Humans; D000077146:Irinotecan; D008130:Lomustine / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077204:Temozolomide
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009607:Nitrosourea Compounds; D011838:Radiation-Sensitizing Agents; D000068258:Bevacizumab; D000077146:Irinotecan; D008130:Lomustine; D003606:Dacarbazine; D002330:Carmustine; D002166:Camptothecin; D000077204:Temozolomide